Anti-tuberculosis immunity by cytotoxic t cells · granulysin and the development of novel vaccines (HSP-65 DNA + IL-12 DNA)

Kekkaku

Volumn 85, Issue 6, 2010, Pages 531-538

  Okada, Masaji ^a   Kita, Yoko ^a  

^a NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

Author keywords

Granulysin; Killer T cell; New TB vaccine

Indexed keywords

BCG VACCINE; DNA; GNLY PROTEIN, HUMAN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 65, HUMAN; HEAT-SHOCK PROTEIN 65, HUMAN; INTERLEUKIN 12; T LYMPHOCYTE ANTIGEN;

ANIMAL; ARTICLE; GENETICS; HUMAN; IMMUNOLOGY; MOUSE; NATURAL KILLER T CELL; TUBERCULOSIS;

ANIMALS; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; DNA; HEAT-SHOCK PROTEINS; HUMANS; INTERLEUKIN-12; MICE; NATURAL KILLER T-CELLS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 77956213930     PISSN: 00229776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Flynn JI., Chan J: Immunology of tuberculosis. Annu Rev Immunol. 2001; 19: 93-129.
2. Okada M, Kita Y, Nakajima T., et al.: Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA + IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB. Vaccine. 2007; 25: 2990-2993.
3. Yoshida S, Tanaka T, Kita Y., et al.: DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. Vaccine. 2006; 24: 1191-1204.
4. The development of novel vaccines against tuberculosis. Jpn J Clin Immunol. 2008; 31: 356-368.
5. Kita Y, Tanaka T, Yoshida S., et al.: Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine. 2005; 23: 2132-2135.
6. Okada M, Kita Y, Nakajima T., et al.: Novel prophylactic and therapeutic vaccine against tuberculosis. Vaccine. 2009; 27: 3267-3270.
7. Stenger S, Hanson DA, Teitelbaum R, et al.: An antimicrobial activity of cytolytic T cells mediated by granulysin. Science. 1998; 282: 121-125.
8. Tanaka F, Abe M, Akiyoshi T., et al.: The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector. Cancer Res. 1997; 57: 1335-1343.
9. Okada M, Yoshimura N, Kaieda T., et al.: Establishment and characterization of human T hybrid cells secreting immu-noregulatory molecules. Proc Natl Acad Sci USA. 1981; 78: 7718-7721.
10. Okada M, Sakaguchi N, Yoshimura N., et al.: B cell growth factors and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation. J Exp Med. 1983; 157: 583-590.
11. Okada M, Kitahara M, Kishimoto S., et al: IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol. 1988; 141: 1543-1549.
12. Okada M, Kita Y: Tuberculosis vaccine development: The development of novel (preclinical) DNA vaccine. Human Vaccine. 2010; 6: 1-12.
13. Okada M, Kita Y, Nakajima T., et al.: Procedia in Vaccinology. Vol. 2, 3rd. Vaccine Global Congress, Singapore, 2009.
14. Skeiky YA, Alderson MR, Ovendale P.J., et al.: Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol. 2004; 172: 7618-7628.
15. McShane H, Pathan AA, Sander C.R., et al.: Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med. 2004; 10: 1240-1244.